Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

NCT04572165 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04572165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
January 26, 2021
Completion date
November 25, 2025
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2